Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech's international, two-cohort, open-label ERIVANCE BCC Phase II study evaluating vismodegib in patients suffering from advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate has met primary endpoint.
Subscribe to our email newsletter
The results from the trial suggested that the drug has helped in shrinking tumors and even healed visible lesions in around 43% of the patients with locally advanced BCC (laBCC) along with 30% of patients with metastatic BCC (mBCC).
In the trial, the subjects received 150mg vismodegib orally, once daily until disease progression or intolerable toxicity.
Genentech Global Product Development head and chief medical officer Hal Barron said their goal is to provide a medicine to people with this rare and disfiguring form of advanced skin cancer as soon as possible, and they are discussing these results with global regulatory authorities.